The gap between the clinical trial and the real world is where decisions are made.
Onco△elta quantifies the delta between clinical trial outcomes and real world patient outcomes across overall response rates, survival, and toxicities. Every figure is traceable to source publications.
Trials are run on ideal patients. Reality looks different.
FDA approval is based on tightly controlled clinical trials with carefully selected patients. Once a drug reaches the real world, the patients receiving it differ and so do the outcomes. Today, no platform makes that difference visible in one place.
Fragmented evidence
Real-world data is buried across ASCO, ASH, ESMO, EHA and journals — much of it behind logins.
No side-by-side view
Clinical-trial and real-world outcomes are never plotted together to reveal the true delta.
A gap between price and real-world value
Drug prices are set on trial results. When real-world benefit comes in lower, payers have limited tools to renegotiate.
Select a disease, a drug, and see the truth
Choose disease & subtype
Pick from NCCN guideline categories and their subtypes.
Select an FDA-approved drug
Drugs approved in the last five years for that indication.
Compare CT vs RWE
ORR, PFS and OS plotted side by side with the delta highlighted.
Ask the AI anything
Draft outcomes-based contracts or RWE study designs in seconds.
Three lenses on every drug
Each visualization compares clinical-trial data against real-world evidence, with the delta — and its source — always in view. Hover any chart to inspect the values.
Overall Response Rate
Percentage of patients achieving response. The bar-by-bar delta is often striking.
Progression-Free Survival
Time patients live without disease progression — trial promise vs real-world reality.
Overall Survival
Kaplan–Meier survival curves comparing trial vs real-world populations over time.
Built on traceable oncology evidence
Every curated pair is cross-checked against primary regulatory, registry, and peer-reviewed literature — with a working source link behind each number.
Source names are used for reference only. OncoDelta is not affiliated with or endorsed by these organizations unless explicitly stated.
One platform, every oncology stakeholder
Pharma
Benchmark real-world performance against the label and competitors.
HEOR
Build value dossiers and outcomes evidence with source-traceable data.
Payers
Tie reimbursement to real-world outcomes with outcomes-based contracts.
P&T Committees
Inform formulary placement decisions and medical policy with trial-versus-real-world evidence.
Providers
Set expectations grounded in real-world evidence, not just trials.
Researchers
Design RWE studies and compare cohorts against curated trial benchmarks.
Evidence intelligence, not just a database
OncoDelta layers AI over the curated catalog to research, summarize, verify, and monitor — always tied back to the underlying sources.
Evidence chatbot
Ask about any drug–indication pair and get answers grounded in the curated evidence, with citations.
HEOR report generator
Draft value dossiers, outcomes summaries, and comparison tables in minutes.
Evidence verification agent
Cross-checks each field against FDA, DailyMed, ClinicalTrials.gov and primary literature — flagging gaps and conflicts.
RWE monitoring
Tracks new real-world and registry studies as they publish, so the evidence stays current.
The most complex disease state in medicine deserves the clearest data.
Be among the first to access OncoDelta — or partner with us to build the value story in oncology.